Morgan Stanley Maintains Overweight on Legend Biotech, Raises Price Target to $85
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Harrison maintains an Overweight rating on Legend Biotech (NASDAQ:LEGN) and raises the price target from $65 to $85.
July 20, 2023 | 1:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley maintains an Overweight rating on Legend Biotech and raises the price target from $65 to $85, indicating a positive outlook for the company.
The raised price target by Morgan Stanley indicates a positive outlook for Legend Biotech. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100